search
Back to results

The Protective Effect of Mask Wearing Against Respiratory Tract Infections

Primary Purpose

COVID-19, Respiratory Tract Infections

Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Wearing face masks
Sponsored by
Norwegian Institute of Public Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for COVID-19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Are at least 18 years of age Are willing to be randomized to wear, or not to wear, face masks outside their home when close to others for a 14-day period Provide informed consent Exclusion Criteria: None

Sites / Locations

  • Norwegian Institute of Public HealthRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Face masks

Not face masks

Arm Description

Participants in the experimental arm are asked to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.

Participants in the no intervention arm arm are asked not to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.

Outcomes

Primary Outcome Measures

Respiratory symptoms of the common cold, influenza or COVID-19
Self-report

Secondary Outcome Measures

Covid-19 prevalence
Self-report
Positive test for SARS-CoV-2
We will compare the incidence of notified cases of COVID-19 (i.e. registered positive SARS-CoV-tests)
Health care use for respiratory symptoms
Self-report
Health care use for injuries
Self-report
Health care use (all causes)
Self-report

Full Information

First Posted
January 11, 2023
Last Updated
March 2, 2023
Sponsor
Norwegian Institute of Public Health
Collaborators
University of Basel
search

1. Study Identification

Unique Protocol Identification Number
NCT05690516
Brief Title
The Protective Effect of Mask Wearing Against Respiratory Tract Infections
Official Title
The Protective Effect of Mask Wearing Against Respiratory Tract Infections: a Pragmatic Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 10, 2023 (Actual)
Primary Completion Date
May 1, 2023 (Anticipated)
Study Completion Date
May 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Norwegian Institute of Public Health
Collaborators
University of Basel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In this trial the researchers plan to recruit 4,000 volunteers to be randomly allocated either wearing face masks in public spaces where they are close to other people, or not wear face masks in such circumstances. For each participant the trial period is 2 weeks, after which they will be asked to complete a brief questionnaire which includes questions about whether they experienced the common cold, influenzas or COVID-19 symptoms during the trail period.
Detailed Description
This study is a pragmatic, two-armed cluster randomized superiority trial including participants in Norway. Participants will be randomized to one of the following two arms: control group or medical masks in a 1:1 ratio. The primary outcome is self-reported respiratory infection. The intervention is to ask participants in the intervention groups to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport. The control group will be asked not to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport. Participants will continue to use, or not use, face masks at work independent of which group they are allocated to. The trial will be fully remote and without any personal interaction between investigators and participants. The researchers aim to include about 4,000 participants to have a statistical power of 80% to detect a relative risk reduction of 30% for the primary outcome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, Respiratory Tract Infections

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Sequence generation. We will use a simple 1:1 randomization by means of computer-generated random numbers. The allocation will be concealed as the participant themselves will be directly informed of their allocation as soon as they have agreed to take part in the trial and have completed the online consent and baseline form. Generation of allocation sequence, enrolment of participants and assignment of participants will all be handled by the digital recruitment platform.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Face masks
Arm Type
Experimental
Arm Description
Participants in the experimental arm are asked to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
Arm Title
Not face masks
Arm Type
No Intervention
Arm Description
Participants in the no intervention arm arm are asked not to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
Intervention Type
Behavioral
Intervention Name(s)
Wearing face masks
Intervention Description
Participants are asked to wear face masks in public spaces.
Primary Outcome Measure Information:
Title
Respiratory symptoms of the common cold, influenza or COVID-19
Description
Self-report
Time Frame
Day 1 to 17
Secondary Outcome Measure Information:
Title
Covid-19 prevalence
Description
Self-report
Time Frame
Day 1 to 17
Title
Positive test for SARS-CoV-2
Description
We will compare the incidence of notified cases of COVID-19 (i.e. registered positive SARS-CoV-tests)
Time Frame
Day 3 to 17 after start of tiral period
Title
Health care use for respiratory symptoms
Description
Self-report
Time Frame
Day 1 to 17
Title
Health care use for injuries
Description
Self-report
Time Frame
Day 1 to 17
Title
Health care use (all causes)
Description
Self-report
Time Frame
Day 1 to 17

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Are at least 18 years of age Are willing to be randomized to wear, or not to wear, face masks outside their home when close to others for a 14-day period Provide informed consent Exclusion Criteria: None
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Runar Solberg, PhD
Phone
+4790979648
Email
Runar.Solberg@fhi.no
First Name & Middle Initial & Last Name or Official Title & Degree
Atle Fretheim, PhD
Email
Atle.Fretheim@fhi.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Runar Solberg, PhD
Organizational Affiliation
Norwegian Institute of Public Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Norwegian Institute of Public Health
City
Oslo
ZIP/Postal Code
0213
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Runar S, PhD
Email
runar.solberg@fhi.no

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The researchers intend to give full access to the protocol, participant level-data dataset and statistical code to anyone who is interested, after securing that the dataset is fully anonymized.
IPD Sharing Time Frame
The investigators expect to be able to share unidentifiable dataset with partners inside the European Union (EU) by May 2023, and an anonymous dataset for wide distribution at a later stage.

Learn more about this trial

The Protective Effect of Mask Wearing Against Respiratory Tract Infections

We'll reach out to this number within 24 hrs